Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Listen to Jeremy S. Abramson, MD, MMSc, discuss the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.
Jeremy S. Abramson, MD, MMSc
Released: March 26, 2021

In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:

  • Approved and Investigational Targeted Therapeutics for CLL
  • Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma
  • Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas
  • Treatment for Older Patients With Hodgkin Lymphoma

Presenters:

Jeremy S. Abramson, MD, MMSc
Associate Professor  
Department of Medicine  
Harvard Medical School  
Director, Center for Lymphoma  
Massachusetts General Hospital  
Boston, Massachusetts

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Gain key clinical insights quickly with this short slideset from CCO on the use of PI3K inhibitors in the treatment of follicular lymphoma.

John M. Burke, MD Nathan H. Fowler, MD Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: June 18, 2021

Podcast with Drs Suzanne Lentzsch and Saad Usmani answering questions on optimal management of relapsed/refractory multiple myeloma (R/R MM) from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP Released: June 17, 2021

Key clinical insights from Drs Suzanne Lentzsch and Saad Usmani on individualizing care for patients with MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP Released: June 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue